Acticor Biotech Book Value Per Share vs. Debt To Equity
| ALACT Stock | EUR 0.25 0.01 3.85% |
For Acticor Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Acticor Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Acticor Biotech SAS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Acticor Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Acticor Biotech SAS over time as well as its relative position and ranking within its peers.
Acticor |
Acticor Biotech SAS Debt To Equity vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Acticor Biotech's current stock value. Our valuation model uses many indicators to compare Acticor Biotech value to that of its competitors to determine the firm's financial worth. Acticor Biotech SAS is number one stock in book value per share category among its peers. It also is number one stock in debt to equity category among its peers fabricating about 1,619 of Debt To Equity per Book Value Per Share. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Acticor Biotech's earnings, one of the primary drivers of an investment's value.Acticor Debt To Equity vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Acticor Biotech |
| = | 0.41 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Acticor Biotech |
| = | 662.10 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Acticor Debt To Equity Comparison
Acticor Biotech is currently under evaluation in debt to equity category among its peers.
Acticor Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Acticor Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Acticor Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Acticor Biotech's change in net profit over the period of time. It can combine multiple indicators of Acticor Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France.
Acticor Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Acticor Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Acticor Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Acticor Biotech's important profitability drivers and their relationship over time.
Use Acticor Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acticor Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acticor Biotech will appreciate offsetting losses from the drop in the long position's value.Acticor Biotech Pair Trading
Acticor Biotech SAS Pair Trading Analysis
The ability to find closely correlated positions to Acticor Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acticor Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acticor Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acticor Biotech SAS to buy it.
The correlation of Acticor Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acticor Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acticor Biotech SAS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acticor Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Acticor Biotech position
In addition to having Acticor Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 71 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.